WO2004086047A3 - Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1) - Google Patents
Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1) Download PDFInfo
- Publication number
- WO2004086047A3 WO2004086047A3 PCT/EP2004/002734 EP2004002734W WO2004086047A3 WO 2004086047 A3 WO2004086047 A3 WO 2004086047A3 EP 2004002734 W EP2004002734 W EP 2004002734W WO 2004086047 A3 WO2004086047 A3 WO 2004086047A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- adora1
- therapeutics
- diagnostics
- protein
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 210000000750 endocrine system Anatomy 0.000 abstract 2
- 208000014951 hematologic disease Diseases 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 102100033346 Adenosine receptor A1 Human genes 0.000 abstract 1
- 101100489791 Homo sapiens ADORA1 gene Proteins 0.000 abstract 1
- 101000799712 Homo sapiens Adenosine receptor A1 Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une ADORA1 humaine associée aux maladies cardio-vasculaires, aux maladies du système endocrinien et hormonal, aux maladies du métabolisme, aux maladies hématologiques, respiratoires, neurologiques ou urologiques. Elle concerne également des méthodes servant à identifier des composés utiles pour le traitement ou la prophylaxie de maladies cardio-vasculaires, de maladies du système endocrinien et hormonal, de maladies du métabolisme, de maladies hématologiques, respiratoires, neurologiques ou urologiques. Elle concerne également des composés se fixant à ADORA1 et/ou activant ou inhibant cette activité, ainsi que des compositions pharmaceutiques contenant ces composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03006847.2 | 2003-03-28 | ||
| EP03006847 | 2003-03-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004086047A2 WO2004086047A2 (fr) | 2004-10-07 |
| WO2004086047A3 true WO2004086047A3 (fr) | 2005-01-20 |
Family
ID=33040915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/002734 WO2004086047A2 (fr) | 2003-03-28 | 2004-03-17 | Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2004086047A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250136658A1 (en) * | 2022-02-01 | 2025-05-01 | The Uab Research Foundation | Anticonvulsant and neuroprotective agent |
| WO2024215814A2 (fr) * | 2023-04-10 | 2024-10-17 | Anand Rene | Procédés et compositions pharmaceutiques pour le traitement du vieillissement |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994019349A1 (fr) * | 1993-02-26 | 1994-09-01 | Merrell Dow Pharmaceuticals Inc. | Derives de xanthine utilises comme antagonistes de recepteurs a1 d'adenosine |
| US5817760A (en) * | 1992-03-13 | 1998-10-06 | Merck & Co., Inc. | Human A3 adenosine receptors |
| US6492377B1 (en) * | 1998-06-25 | 2002-12-10 | Boehringer Ingelheim Pharma Kg | Imidazotriazolopyrimidines with adenosine-antagonistic activity |
| US20030143732A1 (en) * | 2001-04-05 | 2003-07-31 | Kathy Fosnaugh | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA |
-
2004
- 2004-03-17 WO PCT/EP2004/002734 patent/WO2004086047A2/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817760A (en) * | 1992-03-13 | 1998-10-06 | Merck & Co., Inc. | Human A3 adenosine receptors |
| WO1994019349A1 (fr) * | 1993-02-26 | 1994-09-01 | Merrell Dow Pharmaceuticals Inc. | Derives de xanthine utilises comme antagonistes de recepteurs a1 d'adenosine |
| US5840729A (en) * | 1993-02-26 | 1998-11-24 | Merrell Pharmaceuticals Inc. | Xanthine derivatives as adenosine A1 receptor antagonists |
| US6492377B1 (en) * | 1998-06-25 | 2002-12-10 | Boehringer Ingelheim Pharma Kg | Imidazotriazolopyrimidines with adenosine-antagonistic activity |
| US20030143732A1 (en) * | 2001-04-05 | 2003-07-31 | Kathy Fosnaugh | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA |
Non-Patent Citations (1)
| Title |
|---|
| MULLER C E: "A1-adenosine receptor antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS 1997 UNITED KINGDOM, vol. 7, no. 5, 1997, pages 419 - 440, XP002295811, ISSN: 1354-3776 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004086047A2 (fr) | 2004-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005093092A3 (fr) | Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44) | |
| WO2004097421A3 (fr) | Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl) | |
| WO2004099782A3 (fr) | Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g | |
| WO2004086047A3 (fr) | Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1) | |
| WO2005106491A3 (fr) | Diagnostic et traitement therapeutique de maladies associees a la kinase 1 regulee par serum/glucocorticoide (sgk1) | |
| WO2004099783A3 (fr) | Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g | |
| WO2004082570A3 (fr) | Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2) | |
| WO2004086034A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3) | |
| WO2004071378A3 (fr) | Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g | |
| WO2004081563A3 (fr) | Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a) | |
| WO2005093091A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26) | |
| WO2004086052A3 (fr) | Produits de diagnostic et de therapeutique pour des maladies liees au recepteur de l'adenosine a2b couple a la proteine g (adora2b) | |
| WO2005076007A3 (fr) | Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) | |
| WO2004099248A3 (fr) | Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2) | |
| WO2004099781A3 (fr) | Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g | |
| WO2004106935A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103) | |
| WO2005074969A3 (fr) | Diagnostics et traitements de maladies associees au recepteur nucleaire humain nr4a1 (nr4a1) | |
| WO2004080372A3 (fr) | Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4) | |
| WO2004099772A3 (fr) | Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur agtr1a couple aux proteines g (agtr1a) | |
| WO2005113788A3 (fr) | Diagnostics et therapeutiques pour des maladies associees a la kinase 6 associee au recepteur couple a une proteine g (grk6) | |
| WO2005114209A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 2 specifique du recepteur couple a une proteine g (grk2) | |
| WO2004097422A3 (fr) | Diagnostic et traitement de maladies associees au recepteur de la calcitonine (calcr) | |
| WO2005040791A3 (fr) | Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr) | |
| WO2004073587A3 (fr) | Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1) | |
| WO2005103710A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur 1 de l'hormone de liberation de la corticotrophine (crhr1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |